A review in Chest examines the push to extend low-dose CT lung cancer screening beyond heavy smokers, drawing on large Chinese programmes where many lung cancers occur in people with little or no smoking history.
The authors argue three points. Detecting more early-stage cancers is necessary but not sufficient; the reliable sign of benefit is a fall in advanced-stage cancers. Risk models built in smokers work least well in never-smokers, exactly where wider eligibility relies on them. And evidence of benefit should be judged on a continuum, not just trial versus nothing. Data from China and South Korea suggest that spreading CT into average-risk people may add more overdiagnosis than benefit.
The relevance to India is direct: lung cancer in non-smokers is common here, and opportunistic CT screening is increasingly offered privately. The review argues for expansion only within prospective evaluation.
- Offer low-dose CT screening on established smoking-based criteria, where proven benefit lies
- Explain overdiagnosis and false positives before any screening CT in a never-smoker
- Do not interpret more early-stage diagnoses as proof that screening saves lives
- Investigate symptoms promptly in never-smokers rather than relying on screening
Why it matters
Screening never-smokers may find many cancers that would never have harmed them.
Don't overread it
This is an argument-led review, not new trial data; it does not show that screening never-smokers is harmful overall.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for pulmonology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free